Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H18N4O2 |
Molecular Weight | 334.3718 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=C(C2=C(N1)C=CC(=C2)C#N)C3=NC=C(CN4CCOCC4)C=C3
InChI
InChIKey=BLTVBQXJFVRPFK-UHFFFAOYSA-N
InChI=1S/C19H18N4O2/c20-10-13-1-3-16-15(9-13)18(19(24)22-16)17-4-2-14(11-21-17)12-23-5-7-25-8-6-23/h1-4,9,11,22,24H,5-8,12H2
AZ-1080 (AZD-1080) is an inhibitor of GSK-beta which was developed by AstraZeneca and initially tested in patients with Alzheimer’s disease (phase I). The drug was discontinued for the aforementioned condition, but now it is being investigated as a potential therapy for ovarina cancer and emdometrial carcinoma (basic research).
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL262 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23410232 |
31.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
86 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23410232 |
15 mg 1 times / day steady-state, oral dose: 15 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
AZD-1080 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23410232 |
15 mg 1 times / day steady-state, oral dose: 15 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
AZD-1080 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
15 mg 1 times / day steady-state, oral Studied dose Dose: 15 mg, 1 times / day Route: oral Route: steady-state Dose: 15 mg, 1 times / day Sources: Page: p.453 |
healthy, ADULT n = 6 Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 6 Sources: Page: p.453 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23410232
Middle-aged subjects (45–64 years) receive 15 mg AZ-1080 once daily for 14 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23410232
3T3 fibroblasts stably expressing human tau protein were treated with 1 uM of AZ-1080. Dose-dependent inhibition of tau phosphorylation was observed for AZ-1080 with IC50 value of 324 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1969664
Created by
admin on Sat Dec 16 13:22:02 GMT 2023 , Edited by admin on Sat Dec 16 13:22:02 GMT 2023
|
PRIMARY | |||
|
135564570
Created by
admin on Sat Dec 16 13:22:02 GMT 2023 , Edited by admin on Sat Dec 16 13:22:02 GMT 2023
|
PRIMARY | |||
|
612487-72-6
Created by
admin on Sat Dec 16 13:22:02 GMT 2023 , Edited by admin on Sat Dec 16 13:22:02 GMT 2023
|
PRIMARY | |||
|
0TII45R8IJ
Created by
admin on Sat Dec 16 13:22:02 GMT 2023 , Edited by admin on Sat Dec 16 13:22:02 GMT 2023
|
PRIMARY | |||
|
167651
Created by
admin on Sat Dec 16 13:22:02 GMT 2023 , Edited by admin on Sat Dec 16 13:22:02 GMT 2023
|
PRIMARY | |||
|
DTXSID70678598
Created by
admin on Sat Dec 16 13:22:02 GMT 2023 , Edited by admin on Sat Dec 16 13:22:02 GMT 2023
|
PRIMARY |
ACTIVE MOIETY